Pharmazie
Refine
Year of publication
Document Type
- Article (171)
- Doctoral Thesis (92)
- Preprint (3)
- Book (2)
- Conference Proceeding (2)
Language
- English (270) (remove)
Has Fulltext
- yes (270)
Is part of the Bibliography
- no (270)
Keywords
- aging (6)
- inflammation (5)
- 5-lipoxygenase (4)
- Alzheimer-Krankheit (3)
- Apoptosis (3)
- BRD4 (3)
- Entzündung (3)
- Inflammation (3)
- apoptosis (3)
- cancer (3)
- proteomics (3)
- 5-Lipoxygenase (2)
- AML (2)
- Absorption (2)
- Allergie (2)
- Alzheimer (2)
- Alzheimer’s disease (2)
- Boswelliasäuren (2)
- Doxorubicin (2)
- E2F-1 (2)
- HDAC (2)
- IKZF1 (2)
- Immunologie (2)
- Leukotriene (2)
- Lipoxygenase <5-> (2)
- MLL (2)
- MLL-r leukemia (2)
- Mitochondria (2)
- Oxidativer Stress (2)
- PAD4 (2)
- PBPK (2)
- PPARγ (2)
- Proteins (2)
- allostery (2)
- boswellic acid (2)
- bromodomains (2)
- calcium (2)
- citrullination (2)
- cyclooxygenase (2)
- dissolution (2)
- endothelium (2)
- epigenetics (2)
- immune response (2)
- immunology (2)
- inhibitor (2)
- lymphocytes (2)
- mitochondria (2)
- multiple sclerosis (2)
- neuropathic pain (2)
- oxidative stress (2)
- pain (2)
- presenilin-1 (2)
- reactive oxygen species (2)
- soluble epoxide hydrolase (2)
- transcription factor (2)
- transgenic mice (2)
- -MS) (1)
- 1α,25(OH)2D3 (1)
- 2-deoxy-D-ribose (1)
- 5-Lipoxygenase activating protein (FLAP) (1)
- ABCB1 (1)
- AD patients (1)
- AF4 (1)
- AIDS (1)
- AKBA (1)
- API (1)
- APP processing (1)
- ARID5B (1)
- ATAD2 (1)
- Action Plan for Medication Safety (1)
- Activation markers (1)
- Acute leukemia (1)
- Aging (1)
- Alcoholic liver disease (1)
- Allergy (1)
- Alpha-synuclein (1)
- Alter (1)
- Altern (1)
- Alzheimer's Disease (1)
- Alzheimer's disease (1)
- Alzheimer´s Disease (1)
- Amyloid <beta-> (1)
- Amyloid-beta (1)
- Analyse (1)
- Angiogenese (1)
- Anticancer therapy (1)
- Anticoagulation (1)
- Anticonvulsant activity (1)
- Apolipoprotein E (1)
- Apoptose (1)
- Arachidonic acid cascade (1)
- Arachidonsäure (1)
- Arzneimittel (1)
- Autoimmune encephalomyelitis (1)
- Axons (1)
- BDNF (1)
- BRD2 (1)
- BROMO-10 (1)
- Bcl-2 (1)
- Bcl-2 Family Proteins (1)
- Bcl-2 Proteine (1)
- Binding analysis (1)
- Bioavailability (1)
- Biochemie (1)
- Biochemistry (1)
- Bioequivalence (1)
- Biomarkers & Diagnostic Imaging (1)
- Biowaiver (1)
- Birkenpollen (1)
- Blood Brain-Barrier (1)
- Blood brain barrier (1)
- Blut (1)
- Blutstammzelle (1)
- Boswellia serrata (1)
- Boswellic acids (1)
- Bromodomänen (1)
- Butyrate (1)
- CAR T cells (1)
- CD36 (1)
- CD4+ T lymphocytes (1)
- CD69 expression (1)
- CEBPE (1)
- CHRNA10 (1)
- CHRNA7 (1)
- CHRNA9 (1)
- CNS melanoma (1)
- COBL (1)
- CPTAC (1)
- CRC65 (1)
- CRM1 (1)
- Caco-2 cells (1)
- Calcium (1)
- Calliphora (1)
- Cancer (1)
- Cancer cell migration (1)
- Cancer treatment (1)
- Celecoxib (1)
- Cell adhesion (1)
- Cell binding (1)
- Cell biology (1)
- Cell cycle (1)
- Cell differentiation (1)
- Cell signalling (1)
- Cell staining (1)
- Cell therapy (1)
- Cerebral cortex (1)
- Cerebral ischemia (1)
- Chaperones (1)
- Chemical biology (1)
- Chemische Sonden (1)
- Chemoinformatics (1)
- Chemokine (1)
- Chemotaxis (1)
- Chlorides (1)
- Cholesterin Biosyntheseweg (1)
- Chromatin (1)
- Chromatin modelling (1)
- Chromatinmodellierung (1)
- Chromatography (1)
- Chromosomal translocations (1)
- Collagens (1)
- Complex II (1)
- Compound Database (1)
- Connectomics (1)
- Crystal structure (1)
- Curcumin micelles (1)
- Cyclic GMP (1)
- Cyclooxygenases (1)
- Cytochrom P-450 (1)
- Cytokine (1)
- Cytokine expression (1)
- DDDPlus (1)
- DNA Methylation (1)
- DNA-Methylierung (1)
- DYRK1A (1)
- Dendritic structure (1)
- Diabetes mellitus (1)
- Dicer (1)
- Differential Scanning Calorimetry (DSF) (1)
- Diflapolin (1)
- Disease-modifying strategy (1)
- Dissertation (1)
- Doxorubizin (1)
- Doxycycline (1)
- Drosophila melanogaster (1)
- Drug discovery (1)
- Drug safety (1)
- Drug-Drug Interactions (1)
- E-selectin (1)
- E2F-responsive genes (1)
- EGR1/2/3 (1)
- ET-MP (1)
- Electron microscopy (1)
- Electrospray ionisation (ESI) (1)
- Elektrospray-Ionisation (ESI) (1)
- Endothel (1)
- Endothelial cells (1)
- Enzymaktivität (1)
- Epigenetik (1)
- Erythropoiesis (1)
- Experimental autoimmune encephalomyelitis (1)
- Export (1)
- Extracellular matrix (1)
- Extrakt (1)
- FGF-2 KO (1)
- FGFR (1)
- FK506 binding protein (1)
- FRET imaging (1)
- Fenofibrate (1)
- Ficus carica (1)
- FlexTouch (1)
- Flow chamber (1)
- Frankincense (1)
- Free energy (1)
- GI pH (1)
- GI solubility (1)
- Gender (1)
- Gene (1)
- Gene expression (1)
- General practice (1)
- Genetic transduction (1)
- Gentherapie (1)
- Germany (1)
- Glioma (1)
- Glutathione reductase (1)
- Growth factors (1)
- Guanylyl cyclases (1)
- HDACi (1)
- HIV Humanized Mice (1)
- HIV-1 (1)
- HOXA profile (1)
- HOXB4 (1)
- HPLC (1)
- HPLC (-FLD (1)
- Hematopoietic stem cells (1)
- Hepatitis (1)
- Hepatitis B (1)
- High performance liquid chromatography (1)
- Hippocampus (1)
- Histon-Deacetylase-Inhibitoren (1)
- Histon-Deacetylierung (1)
- Histone Deacetylation (1)
- Histone-deacetylase inhibitors (1)
- Homeobox (1)
- Homeodomänenproteine ; Stat1 (1)
- Human Plasma (1)
- Hydrogen bonding (1)
- Hämatopoese (1)
- IFN (1)
- IFN-y (1)
- IL-18 (1)
- IL-18BPa (1)
- IRX1 (1)
- IVIV_E (1)
- Identical Topology (1)
- Immunosenescence (1)
- Immunreaktion (1)
- Immunsystem (1)
- Immuntherapie (1)
- Import (1)
- Indoles (1)
- Infant leukemia (1)
- Instrumentelle Analytik (1)
- Integrins (1)
- Interleukin-22 (1)
- Intracerebroventricular (1)
- Ionenkanal (1)
- Isoprenoide (1)
- Isothermal Titration Calorimetry (ITC) (1)
- Kern-Zytoplasma-Transport (1)
- Kidney (1)
- Kinase inhibitors (1)
- Kinases (1)
- Krankheitsmodulierende Strategien (1)
- LASP1 (1)
- LTP (1)
- Lamivudine (1)
- Lead Structure (1)
- Lebensmittelallergie (1)
- Lecithin (1)
- Leishmania infantum (1)
- Leukotrienes (1)
- Lipid peroxidation (1)
- Lipid raft (1)
- Lipid-based formulation (1)
- Lipidperoxidation (1)
- Lipoxygenaseinhibitor (1)
- Liver cirrhosis (1)
- Liver-related complications (1)
- Lpar2 (1)
- Luciferase (1)
- Lymphocytes (1)
- Lysophosphatidic acids (1)
- MALDI MS (1)
- MAML2 (1)
- MAP-Kinase (1)
- MAPKinase (1)
- MEIS2 (1)
- MELD (1)
- MKP1 (1)
- MLL fusion proteins (1)
- MLV (1)
- MVA-pathway (1)
- MYC (1)
- Machine learning (1)
- Maillard reaction (1)
- Maillard-Reaktion (1)
- Malaria (1)
- Market Access (1)
- Matrix assisted laser desorption/ionisation (MALDI) (1)
- Matrix-unterstützte Laser-Desorption (MALDI) (1)
- Mechanisms of disease (1)
- Medication changes (1)
- Medizinische Chemie (1)
- Mefloquine (1)
- Mesenchymale Stammzellen (1)
- Mesenchymzelle (1)
- Metabolic syndrome (1)
- Metabolism (1)
- Mice (1)
- Microbiology (1)
- Migration <Biologie> (1)
- Mitochondrial dysfunction (1)
- Mitochondrien (1)
- Molecular association (1)
- Molecular docking (1)
- Molecular mechanisms of cancer (1)
- Molecular medicine (1)
- Moraceae (1)
- Motor neurons (1)
- Multimorbidity (1)
- Multiple chronic conditions (1)
- Mutant p53 (1)
- Myelopoiesis (1)
- NEBL (1)
- NES (1)
- NFAT (1)
- NFκB (1)
- NLS (1)
- NMR Spectroscopy (1)
- NO-GC stimulators (1)
- Nano-ESI MS (1)
- Nanoparticle (1)
- Nanoparticles (1)
- Nanopartikel (1)
- Natriuretic peptides (1)
- Naturheilkunde (1)
- Nervendegeneration (1)
- Neurodegeneration (1)
- Neuroinflammation (1)
- Neuronal dendrites (1)
- Neurons (1)
- Neuroscience (1)
- Nichtsteroidales Antiphlogistikum (1)
- Nitric oxide (1)
- Npr2 (1)
- Nrf2 (1)
- Older adults (1)
- Olibanum (1)
- Open Access (1)
- Oxidative phosphorylation (1)
- Oxidative stress (1)
- P2X3 (1)
- P2X7 receptor (1)
- PBX1 (1)
- PC12 cells (1)
- PGC-1 alpha (1)
- PPAR gamma activator (1)
- Pairwise Sequence Alignment (1)
- Parietal cortex (1)
- Parkinson’s disease (1)
- Patch-Clamp-Methode (1)
- Pathogenesis (1)
- Permeability (1)
- Peroxisome Proliferator-Activated Rezeptor (PPARgamma) (1)
- Pharma Management (1)
- Pharmacodynamics (1)
- Pharmacokinetic Interactions (1)
- Pharmacology (1)
- Phosphodiesterases (1)
- Phospholipide (1)
- Phosphorylierung (1)
- Physical and chemical properties (1)
- Polypharmacy (1)
- Presenilin (1)
- Preseniline (1)
- Proliferation (1)
- Promoter (1)
- Promotor (1)
- Proteomics (1)
- Purkinje cells (1)
- Quality Control (1)
- Quinine (1)
- R software (1)
- RAG (1)
- RNA-templated DNA repair (1)
- RXRα (1)
- Reactive oxygen species (1)
- Regulatory Affairs (1)
- Research & Development (1)
- Rho GTPasen (1)
- SAMHD1 knockout mouse (1)
- SAMHD1 phosphorylation (1)
- SAVI (1)
- SKNSH-SY5Y neuroblastoma cells (1)
- SMAD (1)
- SMAP1 (1)
- SSR128129E (1)
- STING (1)
- STK3 (1)
- Secondary mutations (1)
- Secretase Inhibitors (1)
- Sekretase Inhibitoren (1)
- Selbsterneuerung (1)
- Self-renewal (1)
- Sequence motif analysis (1)
- Slack (1)
- Slack channel (1)
- Smads (1)
- SoloSTAR (1)
- Soluble epoxide hydrolase (sEH) (1)
- Sp1 (1)
- Spinal cord (1)
- Stammzell-Therapie (1)
- Stammzellentransplantation (1)
- Stat1 (1)
- Structure-based drug discovery (1)
- Strukturbasiertes Design (1)
- Substituierte Pyrimidine (1)
- Substituted Pyrimidines (1)
- Superoxiddismutase (1)
- Superoxide dismutase (1)
- Survivin (1)
- Synapses (1)
- T lymphocyte subsets (1)
- T-cell homing (1)
- T-cell targeting (1)
- TALE-homdomain protein (1)
- TGFβ (1)
- Target identification (1)
- Target validation (1)
- Thrombozyten (1)
- Toll-like receptors (1)
- Toll-like-Rezeptoren (1)
- Tools and resources (1)
- Transcription factors (1)
- Transcriptional control (1)
- Transepithelial transport (1)
- Transkriptionsfaktor (1)
- Transkriptionsfaktoren (1)
- Translocation partner genes (1)
- Trichostatin A (1)
- Triterpenoids (1)
- Tuberculosis (1)
- Tween 80 (1)
- Tyrosine phosphorylation (1)
- UCN-01 (1)
- VDR (1)
- Validierung (1)
- Virtual Screening (1)
- Vision (1)
- Vitamin D (1)
- Vitamin D Rezeptor (VDR) (1)
- WHO Prequalification of Medicines Programme (1)
- WT1 (1)
- Wachstumsfaktor (1)
- Weihrauch (1)
- Weihrauchstrauch (1)
- Wirkstoff (1)
- Wnt (1)
- X-ray structure analysis (1)
- Yeast-Two-Hybrid-System (1)
- Zell-basierte Assaysysteme (1)
- Zelladhäsion (1)
- Zellmigration (1)
- acute lymphoblastic leukemia (1)
- alzheimer’s disease (1)
- amorphous stability (1)
- amyloid precursor protein (1)
- amyloid precursor protein (APP) (1)
- analgesia (1)
- analytics (1)
- androgen receptor (1)
- angiogenesis (1)
- anti-CD3 (1)
- anti-CXCL10 (1)
- anticonvulsants (1)
- antioxidants (1)
- aprepitant (1)
- arachidonate (1)
- axon bifurcation (1)
- axonal pathfinding (1)
- bicarbonates (1)
- bio-enabling formulations (1)
- biochemistry (1)
- bioinformatics (1)
- biopharmaceutics (1)
- biorelevant dissolution tests (1)
- biorelevant media (1)
- biosimilar and analogue insulins (1)
- biosynthetic human insulin (1)
- blood (1)
- blood–brain barrier (1)
- boswellic acids (1)
- bromodomain inhibitor (1)
- buffer capacity (1)
- cGKI (1)
- cGMP (1)
- calcitriol (1)
- calcium-independent phospholipase A2β (1)
- caspase (1)
- castration-resistant prostate cancer (1)
- cathepsin (1)
- celecoxib (1)
- cell death (1)
- cell-based assay-systems (1)
- cerebellar granule cells (1)
- cerebral ischemia (1)
- chemical biology (1)
- chemical probes (1)
- cholesterol (1)
- chondrocytes (1)
- chromatin (1)
- chronobiology (1)
- citrate (1)
- cofactor recruitment (1)
- controlled nuclear import (1)
- cost (1)
- cyclodextrine (1)
- cytochrome P450 (1)
- cytochrome c. (1)
- dalargin (1)
- data modeling (1)
- day time dependent transport (1)
- dementia (1)
- designed multitarget ligands (1)
- deubiquitylating enzymes (1)
- development (1)
- disintegration (1)
- disposable insulin pens (1)
- dissertation (1)
- dissolution modeling (1)
- docosahexaenoic acid (1)
- dorsal root ganglia (1)
- dosing accuracy (1)
- drug resistance (1)
- drug response (1)
- drug target (1)
- drug–drug interaction (DDI) (1)
- eicosanoid (1)
- electrophiles (1)
- electrophysiology (1)
- enhancer of transcription (1)
- enzyme mechanism (1)
- epigenetic (1)
- epilepsy (1)
- epileptic encephalopathies (1)
- epithelial cells (1)
- epithelium (1)
- export (1)
- extracellular matrix (1)
- fluorescence confocal laser scanning microscopy (1)
- fluorescent ligand (1)
- food allergy (1)
- forkhead box protein o1 (1)
- frankincense (1)
- gastrointestinal drugs (1)
- gender (1)
- gene therapy (1)
- genes (1)
- genetic rearrangements (1)
- glass forming ability (1)
- global access (1)
- glucose (1)
- guanylyl cyclase (1)
- heterodimer (1)
- hippocampal neurons (1)
- hippocampus (1)
- homeobox (1)
- homeodomain proteins (1)
- homing (1)
- homodimer (1)
- homogeneous time-resolved FRET (HTRF) (1)
- hotmelt extrusion (1)
- human histamine H3 receptor (1)
- human intestinal fluid (1)
- hydroxysafflor yellow A (1)
- hyperalgesia (1)
- hämatopoetischer Stammzellen (1)
- immortalized porcine brain microvascular endothelial cells (1)
- immune system (1)
- immunofluorescence (1)
- immunomodulation (1)
- import (1)
- in vitro in vivo extrapolation (IVIVE) (1)
- in vitro model (1)
- in vivo gene delivery (1)
- incense (1)
- indole (1)
- indomethacin (1)
- inflammasome (1)
- innate immune system (1)
- interleukin-1β (1)
- interleukin-2 gene (1)
- interleukins (1)
- isoforms (1)
- isoprenoids (1)
- ketoconazole (1)
- ketone bodies (1)
- kolorektales Karzinom (1)
- lactate (1)
- leukemia; solid tumors (1)
- leukocyte-endothelial cell interaction (1)
- levetiracetam (1)
- loxapine (1)
- lymphocyte (1)
- mPGES-1 (1)
- mass spectrometry (1)
- mechanistic oral absorption modeling (1)
- medication plan (1)
- medication schedule (1)
- medicinal chemistry (1)
- membrane fluidity (1)
- membrane transport (1)
- mesoporous silica (1)
- metabolic syndrome (1)
- miRNA in immune cells (1)
- mice (1)
- microsomal prostaglandin E2 synthase (1)
- middle cerebral artery occlusion (1)
- mitochondrial dysfunction (1)
- mitosis (1)
- model fitting (1)
- modeling and simulation (1)
- molecular docking (1)
- molecular marker (1)
- molecular mechanisms (1)
- montelukast (1)
- mouse (1)
- nano-sized drugs (1)
- nanoparticles (1)
- nephelometry (1)
- neurodegeneration (1)
- neurogenesis (1)
- neurosciences (1)
- nitric oxide (1)
- nitro-fatty acids (1)
- nociception and pain (1)
- nukleäre Hormonrezeptoren (1)
- oral absorption (1)
- oxidative (1)
- oxylipin (1)
- p38 MAP kinase (1)
- p53 (1)
- pH (1)
- palmitoylation (1)
- patch clamp technique (1)
- patient safety (1)
- patient stratification (1)
- personalized medicine (1)
- pharmacogenetics (1)
- pharmacokinetics (1)
- pharmacokinetics/pharmacodynamics (PK/PD) (1)
- pharmacological tool (1)
- pharmacotherapy (1)
- phenotype (1)
- phospholipids (1)
- phosphorylcholine (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- physiologically based pharmacokinetic model (1)
- piracetam (1)
- pirinixic acid (1)
- pirinixic acid derivative (1)
- platelets (1)
- polypharmacology (1)
- poorly soluble drugs (1)
- posttranslational modification (1)
- pranlukast (1)
- precipitation (1)
- premature transcript termination (1)
- presynaptic active zone (1)
- pretubulysin (1)
- prevention (1)
- product specification (1)
- programmed cell death (1)
- promastigote (1)
- prostaglandin (1)
- protein kinase inhibitor (1)
- proto-oncogene proteins c-akt (1)
- quality-by-design (1)
- rapamycin (1)
- receptor targeting (1)
- recurrent chromosomal translocations (1)
- regulatory requirements (1)
- relapse (1)
- renal fibrosis (1)
- resveratrol (1)
- rice bran extract (1)
- rna (1)
- secondary active transport (1)
- seizure (1)
- sensory neurons (1)
- sepsis (1)
- siRNA (1)
- signal transduction (1)
- simplified media (1)
- site-directed mutagenesis (1)
- small intestine (1)
- sodium-proton exchange (1)
- solubility (1)
- spinal cord (1)
- statin (1)
- stem cell niche (1)
- stomach (1)
- striatum (1)
- structure-based design (1)
- subventricular zone (1)
- succinate (1)
- supersaturation (1)
- surfactants (1)
- survivin (1)
- tetracycline (1)
- tocopherol (1)
- tocotrienol (1)
- tolerability and safety (1)
- toxins (1)
- tp63 gene (1)
- traget-fishing (1)
- transcription factors (1)
- transport mechanism (1)
- transporter (1)
- triterpene acid (1)
- trkB (1)
- tumor cell adhesion (1)
- tumor cell transmigration (1)
- tumor vaccines (1)
- type 1 diabetes (1)
- ubiquitin specific proteases (1)
- validation (1)
- vitamin E (1)
- yeast two-hybrid system (1)
- zafirlukast (1)
- β-Catenin (1)
- β-catenin (1)
- β‐hydroxybutyrate (1)
Institute
- Pharmazie (270)
- Medizin (48)
- Biochemie und Chemie (21)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (19)
- Biowissenschaften (8)
- Georg-Speyer-Haus (7)
- Exzellenzcluster Makromolekulare Komplexe (6)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (3)
- MPI für Hirnforschung (2)
- Sonderforschungsbereiche / Forschungskollegs (2)
Chemokines play a key role in the cellular infiltration of inflamed tissue. They are released by a wide variety of cell types during the initial phase of host response to injury, allergens, antigens, or invading microorganisms, and selectively attract leukocytes to inflammatory foci, inducing both migration and activation. Monocyte chemoattractant protein-1 (MCP-1), a member of the CC chemokine superfamily, functions in attracting monocytes, T lymphocytes, and basophils to sites of inflammation. MCP-1 is produced by monocytes, fibroblasts, vascular endothelial cells and smooth muscle cells in response to various stimuli such as tumour necrosis factor-a (TNF-a), interferon-g (IFN-g), and interleukin-1b (IL-1b). It also plays an important role in the pathogenesis of chronic inflammation, and overexpression of MCP-1 has been implicated in diseases including glomerulonephritis and rheumatoid arthritis. Oligonucleotide-directed triple helix formation offers a means to target specific sequences in DNA and interfere with gene expression at the transcriptional level. Triple helix-forming oligonucleotides (TFOs) bind to homopurine/homopyrimidine sequences, forming a stable, sequence-specific complex with the duplex DNA. Purine-rich sequences are frequent in gene regulatory regions and TFOs directed to promoter sequences have been shown to prevent binding of transcription factors and inhibit transcription initiation and elongation. Exogenous TFOs that bind homopurine/ homopyrimidine DNA sequences and form triple-helices can be rationally designed, while the intracellular delivery of single-stranded RNA TFOs has not been studied in detail before. In this study, expression vectors were constructed which directed transcription of either a 19 nt triplex-forming pyrimidine CU-TFO sequence targeting the human MCP-1 or two different 19 nt GU- or CA-control sequences, respectively, together with the vector encoded hygromycin resistance mRNA as one fusion transcript. HEK 293 cells were stable transfected with these vectors and several TFO and control cell lines were generated. Functional relevant triplex formation of a TFO with a corresponding 19 bp GC-rich AP-1/SP-1 site of the human MCP-1 promoter was shown. Binding of synthetic 19 nt CUTFO to the MCP-1 promoter duplex was verified by triplex blotting at pH 6.7. Underlining binding specificity, control sequences, including the GU- and CA-sequence, a TFO containing one single mismatch and a MCP-1 promoter duplex containing two mismatches, did not participate in triplex formation. Establishing a magnetic capture technique with streptavidin microbeads it was verified that at pH 7.0 the 19 nt TFO embedded in a 1.1 kb fusion transcript binds to a plasmid encoded MCP-1 promoter target duplex three times stronger than the controls. Finally, cell culture experiments revealed 76 ± 10.2% inhibition of MCP-1 protein secretion in TNF-a stimulated CU-TFO harboring cell lines and up to 88% after TNF-a and IFN-g costimulation in comparison to controls. Expression of interleukin-8 (IL-8) as one TNF-a inducible control gene was not affected by CU-TFO, demonstrating both highly specific and effective chemokine gene repression. Furthermore, another chemokine target, regulated upon activation normal T cell expressed and secreted (RANTES), which plays an essential role in inflammation by recruiting T lymphocytes, macrophages and eosinophils to inflammatory sites, was analysed using the triplex approach. A 28 nt TFO was designed targeting the murine RANTES gene promoter, and gel mobility shift assays demonstrated that the phosphodiester TFO formed a sequencespecific triplex with the double-stranded target DNA with a Kd of 2.5 x 10-7 M. It was analysed whether RANTES expression could be inhibited at the transcriptional level testing the TFO in two different cell lines, T helper-1 lymphocytes and brain microvascular endothelial cells (bend3 cells). Although there was a sequence-specific binding of the TFO detectable in the gel shift assays, there was no inhibitory effect of the exogenously added and phosphorothioate stabilised TFO on endogenous RANTES gene expression visible. Additionally, the small interfering RNA (siRNA) approach was tested as another strategy to inhibit expression of the pro-inflammatory chemokines MCP-1 and RANTES. Two different methods were pursuit, describing transient transfection with vector derived and synthetic siRNA. The vector pSUPER containing the siRNA coding sequence was used to suppress endogenous MCP-1 in HEK 293 cells. An empty vector without RNA sequence served as a control. Inhibition due to the siRNA was measured in stimulated and unstimulated cells. In TNF-a stimulated cells MCP-1 protein synthesis was decreased by 35 ± 11% after siRNA transfection. Using a synthetic double-stranded siRNA, the TNF-a induced MCP-1 protein secretion could be successfully inhibited about 62.3 ± 10.3% in HEK 293 cells, indicating that the siRNA is functional in these cells to suppress chemokine expression. The siRNA approach targeting murine RANTES in Th1 cells and b-end3 cells revealed no inhibition of endogenous gene expression. Gene therapy approaches rely on efficient transfer of genes to the desired target cells. A wide variety of viral and nonviral vectors have been developed and evaluated for their efficiency of transduction, sustained expression of the transgene, and safety. Among them, lentiviruses have been widely used for gene therapy applications. In order to improve the delivery of TFOs or siRNAs into the target cells, cloning of the lentiviral transfer vector SEW, the production of lentiviral particles by transient transfection were performed with the aim to generate lentiviral vector-derived TFOs in further experiments. Here, Th1 cells were transduced with infectious lentiviral particles and transduction efficacy was measured. Transduction efficacy higher than 82% could be achieved using the lentiviral vector SEW, opening optimal possibilities for the TFO or siRNA approach.
Patient therapy is based mainly on a combination of diagnosis, suitable monitoring or support devices and drug treatment and is usually employed for a pre-existing disease condition. Therapy remains predominantly symptom-based, although it is increasingly clear that individual treatment is possible and beneficial. However, reasonable precision medicine can only be realized with the coordinated use of diagnostics, devices and drugs in combination with extensive databases (4Ds), an approach that has not yet found sufficient implementation. The practical combination of 4Ds in health care is progressing, but several obstacles still hamper their extended use in precision medicine.
5-Lipoxygenase contributes to PPAR [gamma] activation in macrophages in response to apoptotic cells
(2012)
Background: One hallmark contributing to immune suppression during the late phase of sepsis is macrophage polarization to an anti-inflammatory phenotype upon contact with apoptotic cells (AC). Taking the important role of the nuclear receptor PPARγ for this phenotype switch into consideration, it remains elusive how AC activate PPARγ in macrophages. Therefore, we were interested to characterize the underlying principle.
Methods: Apoptosis was induced by treatment of Jurkat T cells for 3 hours with 0.5 μg/ml staurosporine. Necrotic cells (NC) were prepared by heating cells for 20 minutes to 65°C. PPARγ activation was followed by stably transducing RAW264.7 macrophages with a vector encoding the red fluorescent protein mRuby after PPARγ binding to 4 × PPRE sites downstream of the reporter gene sequence. This readout was established by treatment with the PPARγ agonist rosiglitazone (1 μM) and AC (5:1). Twenty-four hours after stimulation, mRuby expression was analysed by fluorescence microscopy. Lipid rafts of AC, NC, as well as living cells (LC) were enriched by sucrose gradient centrifugation. Fractions were analysed for lipid raft-associated marker proteins. Lipid rafts were incubated with transduced RAW264.7 macrophages as described above. 5-Lipoxygenase (5-LO) involvement was verified by pharmacological inhibition (MK-866, 1 μM) and overexpression.
Results: Assuming that the molecule responsible for PPARγ activation in macrophages is localized in the cell membrane of AC, most probably associated to lipid rafts, we isolated lipid rafts from AC, NC and LC. Mass spectrometric analysis of lipid rafts of AC showed the expression of 5-LO, whereas lipid rafts of LC did not. Moreover, incubating macrophages with lipid rafts of AC induced mRuby expression. In contrast, lipid rafts of NC and LC did not. To verify the involvement of 5-LO in activating PPARγ in macrophages, Jurkat T cells were incubated for 30 minutes with the 5-LO inhibitor MK-866 (1 μM) before apoptosis induction. In line with our hypothesis, these AC did not induce mRuby expression. Finally, although living Jurkat T cells overexpressing 5-LO did not activate PPARγ in macrophages, mRuby expression was significantly increased when AC were generated from 5-LO overexpressing compared with wild-type Jurkat cells.
Conclusion: Our results suggest that induction of apoptosis activates 5-LO, localizing to lipid rafts, necessary for PPARγ activation in macrophages. Therefore, it will be challenging to determine whether 5-LO activity in AC, generated from other cell types, correlates with PPARγ activation, contributing to an immune-suppressed phenotype in macrophages.
Since hyperactivity of the protein kinase DYRK1A is linked to several neurodegenerative disorders, DYRK1A inhibitors have been suggested as potential therapeutics for Down syndrome and Alzheimer’s disease. Most published inhibitors to date suffer from low selectivity against related kinases or from unfavorable physicochemical properties. In order to identify DYRK1A inhibitors with improved properties, a series of new chemicals based on [b]-annulated halogenated indoles were designed, synthesized, and evaluated for biological activity. Analysis of crystal structures revealed a typical type-I binding mode of the new inhibitor 4-chlorocyclohepta[b]indol-10(5H)-one in DYRK1A, exploiting mainly shape complementarity for tight binding. Conversion of the DYRK1A inhibitor 8-chloro-1,2,3,9-tetrahydro-4H-carbazol-4-one into a corresponding Mannich base hydrochloride improved the aqueous solubility but abrogated kinase inhibitory activity.
Bromodomains (BRDs) are conserved protein interaction modules which recognize (read) acetyl-lysine modifications, however their role(s) in regulating cellular states and their potential as targets for the development of targeted treatment strategies is poorly understood. Here we present a set of 25 chemical probes, selective small molecule inhibitors, covering 29 human bromodomain targets. We comprehensively evaluate the selectivity of this probe-set using BROMOscan and demonstrate the utility of the set identifying roles of BRDs in cellular processes and potential translational applications. For instance, we discovered crosstalk between histone acetylation and the glycolytic pathway resulting in a vulnerability of breast cancer cell lines under conditions of glucose deprivation or GLUT1 inhibition to inhibition of BRPF2/3 BRDs. This chemical probe-set will serve as a resource for future applications in the discovery of new physiological roles of bromodomain proteins in normal and disease states, and as a toolset for bromodomain target validation.
The prediction of protein–ligand interactions and their corresponding binding free energy is a challenging task in structure-based drug design and related applications. Docking and scoring is broadly used to propose the binding mode and underlying interactions as well as to provide a measure for ligand affinity or differentiate between active and inactive ligands. Various studies have revealed that most docking software packages reliably predict the binding mode, although scoring remains a challenge. Here, a diverse benchmark data set of 99 matched molecular pairs (3D-MMPs) with experimentally determined X-ray structures and corresponding binding affinities is introduced. This data set was used to study the predictive power of 13 commonly used scoring functions to demonstrate the applicability of the 3D-MMP data set as a valuable tool for benchmarking scoring functions.
Background: Human genetic research has implicated functional variants of more than one hundred genes in the modulation of persisting pain. Artificial intelligence and machine‐learning techniques may combine this knowledge with results of genetic research gathered in any context, which permits the identification of the key biological processes involved in chronic sensitization to pain.
Methods: Based on published evidence, a set of 110 genes carrying variants reported to be associated with modulation of the clinical phenotype of persisting pain in eight different clinical settings was submitted to unsupervised machine‐learning aimed at functional clustering. Subsequently, a mathematically supported subset of genes, comprising those most consistently involved in persisting pain, was analysed by means of computational functional genomics in the Gene Ontology knowledgebase.
Results: Clustering of genes with evidence for a modulation of persisting pain elucidated a functionally heterogeneous set. The situation cleared when the focus was narrowed to a genetic modulation consistently observed throughout several clinical settings. On this basis, two groups of biological processes, the immune system and nitric oxide signalling, emerged as major players in sensitization to persisting pain, which is biologically highly plausible and in agreement with other lines of pain research.
Conclusions: The present computational functional genomics‐based approach provided a computational systems‐biology perspective on chronic sensitization to pain. Human genetic control of persisting pain points to the immune system as a source of potential future targets for drugs directed against persisting pain. Contemporary machine‐learned methods provide innovative approaches to knowledge discovery from previous evidence.
Significance: We show that knowledge discovery in genetic databases and contemporary machine‐learned techniques can identify relevant biological processes involved in Persitent pain.
Background: The oral administration of the gum resin extracts of Indian frankincense (Boswellia serrata Roxb. ex Colebr) results in very low plasma concentrations of boswellic acids (BAs), being far below the pharmacologically active concentrations required in vitro for anti-inflammatory activity. For that reason the use of Indian frankincense in clinical practice and pharmaceutical development has substantially lagged behind. Recently the application of new formulation technologies resulted in a formulation of frankincense extract with lecithin, which revealed improved absorption and tissue penetration of BAs in a rodent study, leading for the first time to plasma concentrations of BAs in the range of their anti-inflammatory activity.
Purpose: In order to verify these encouraging results in humans, the absorption of a standardized Boswellia serrata extract (BE) and its lecithin formulation (CSP) was comparatively investigated in healthy volunteers.
Study design: According to a randomized cross-over design with two treatments, two sequences and two periods, 12 volunteers alternatively received the lecithin-formulated Boswellia extract (CSP) or the non-formulated Boswellia extract (BE) at a dosage of 2 × 250 mg capsules.
Methods: The plasma concentrations of the six major BAs (KBA, AKBA, βBA, αBA, AβBA, AαBA) were determined using LC/MS.
Results: With the exception of KBA, a significantly higher (both in terms of weight-to-weight and molar comparison) and quicker absorption of BAs from the lecithin formulation was observed, leading to Cmax in the range required for the interaction with their molecular targets.
Conclusion: These findings pave the way to further studies evaluating the clinical potential of BAs, and verify the beneficial effect of lecithin formulation to improve the absorption of poorly soluble phytochemicals.
CD4+CD25+ regulatory T cells (Tregs) represent a specialized subpopulation of T cells, which are essential for maintaining peripheral tolerance and preventing autoimmunity. The immunomodulatory effects of Tregs depend on their activation status. Here we show that, in contrast to conventional anti-CD4 monoclonal antibodies (mAbs), the humanized CD4-specific monoclonal antibody tregalizumab (BT-061) is able to selectively activate the suppressive properties of Tregs in vitro. BT-061 activates Tregs by binding to CD4 and activation of signaling downstream pathways. The specific functionality of BT-061 may be explained by the recognition of a unique, conformational epitope on domain 2 of the CD4 molecule that is not recognized by other anti-CD4 mAbs. We found that, due to this special epitope binding, BT-061 induces a unique phosphorylation of T-cell receptor complex-associated signaling molecules. This is sufficient to activate the function of Tregs without activating effector T cells. Furthermore, BT-061 does not induce the release of pro-inflammatory cytokines. These results demonstrate that BT-061 stimulation via the CD4 receptor is able to induce T-cell receptor-independent activation of Tregs. Selective activation of Tregs via CD4 is a promising approach for the treatment of autoimmune diseases where insufficient Treg activity has been described. Clinical investigation of this new approach is currently ongoing.
Activation of Mitochondrial complex II-dependent respiration is beneficial for α-Synucleinopathies
(2015)
Parkinson’s disease and dementia with Lewy bodies are major challenges in research and clinical medicine world-wide and contribute to the most common neurodegenerative disorders. Previously, specific mitochondrial polymorphisms have been found to enhance clearance of amyloid-β from the brain of APP-transgenic mice leading to beneficial clinical outcome. It has been discussed whether specific mitochondrial alterations contribute to disease progression or even prevent toxic peptide deposition, as seen in many neurodegenerative diseases. Here, we investigated α-synuclein-transgenic C57BL/6J mice with the A30P mutation, and a novel A30P C57BL/6J mouse model with three mitochondrial DNA polymorphisms in the ND3, COX3 and mtRNAArg genes, as found in the inbred NOD/LtJ mouse strain. We were able to detect that the new model has increased mitochondrial complex II-respiration which occurs in parallel to neuronal loss and improved motor performance, although it exhibits higher amounts of high molecular weight species of α-synuclein. High molecular weight aggregates of different peptides are controversially discussed in the light of neurodegeneration. A favourable hypothesis states that high molecular weight species are protective and of minor importance for the pathogenesis of neurodegenerative disorders as compared to the extreme neurotoxic monomers and oligomers. Summarising, our results point to a potentially protective and beneficial effect of specific mitochondrial polymorphisms which cause improved mitochondrial complex II-respiration in α-synucleinopathies, an effect that could be exploited further for pharmaceutical interventions.
Rho-family GTPases like RhoA and Rac-1 are potent regulators of cellular signaling that control gene expression, migration and inflammation. Activation of Rho-GTPases has been linked to podocyte dysfunction, a feature of chronic kidney diseases (CKD). We investigated the effect of Rac-1 and Rho kinase (ROCK) inhibition on progressive renal failure in mice and studied the underlying mechanisms in podocytes. SV129 mice were subjected to 5/6-nephrectomy which resulted in arterial hypertension and albuminuria. Subgroups of animals were treated with the Rac-1 inhibitor EHT1846, the ROCK inhibitor SAR407899 and the ACE inhibitor Ramipril. Only Ramipril reduced hypertension. In contrast, all inhibitors markedly attenuated albumin excretion as well as glomerular and tubulo-interstitial damage. The combination of SAR407899 and Ramipril was more effective in preventing albuminuria than Ramipril alone. To study the involved mechanisms, podocytes were cultured from SV129 mice and exposed to static stretch in the Flexcell device. This activated RhoA and Rac-1 and led via TGFβ to apoptosis and a switch of the cells into a more mesenchymal phenotype, as evident from loss of WT-1 and nephrin and induction of α-SMA and fibronectin expression. Rac-1 and ROCK inhibition as well as blockade of TGFβ dramatically attenuated all these responses. This suggests that Rac-1 and RhoA are mediators of podocyte dysfunction in CKD. Inhibition of Rho-GTPases may be a novel approach for the treatment of CKD.
This open access book presents a unique collection of practical examples from the field of pharma business management and research. It covers a wide range of topics such as: "Brexit and its Impact on pharmaceutical Law - Implications for Global Pharma Companies", "Implementation of Measures and Sustainable Actions to Improve Employee's Engagement", "Global Medical Clinical and Regulatory Affairs (GMCRA)", and "A Quality Management System for R&D Project and Portfolio Management in a Pharmaceutical Company".
The chapters are summaries of master’s theses by "high potential" Pharma MBA students from the Goethe Business School, Frankfurt/Main, Germany, with 8-10 years of work experience and are based on scientific know-how and real-world experience. The authors applied their interdisciplinary knowledge gained in 22 months of studies in the MBA program to selected practical themes drawn from their daily business.
The human 5-lipoxygenase (5-LO), encoded by the ALOX5 gene, is the key enzyme in the formation of pro-inflammatory leukotrienes. ALOX5 gene transcription is strongly stimulated by calcitriol (1α, 25-dihydroxyvitamin D3) and TGFβ (transforming growth factor-β). Here, we investigated the influence of MLL (activator of transcript initiation), AF4 (activator of transcriptional elongation) as well as of the leukemogenic fusion proteins MLL-AF4 (ectopic activator of transcript initiation) and AF4-MLL (ectopic activator of transcriptional elongation) on calcitriol/TGFβ-dependent 5-LO transcript elongation. We present evidence that the AF4 complex directly interacts with the vitamin D receptor (VDR) and promotes calcitriol-dependent ALOX5 transcript elongation. Activation of transcript elongation was strongly enhanced by the AF4-MLL fusion protein but was sensitive to Flavopiridol. By contrast, MLL-AF4 displayed no effect on transcriptional elongation. Furthermore, HDAC class I inhibitors inhibited the ectopic effects caused by AF4-MLL on transcriptional elongation, suggesting that HDAC class I inhibitors are potential therapeutics for the treatment of t(4;11)(q21;q23) leukemia.
Apoptosis seems to be involved in immunosenescence associated with aging. Moreover, in lymphocytes (PBL) of patients with Alzheimer's disease, an increased susceptibility to the apoptotic pathway has been described possibly due to impaired protection of oxidative stress. Accordingly, it seemed to be of particular interest to investigate the contribution of normal aging to the susceptibility from human lymphocytes to programmed cell death. We could show that PBL from elderly individuals (>60 years) accumulate apoptosing cells to a significant higher extent in spontaneous and activation-induced cell death compared to younger controls (<35 years). Treatment with the oxidative stressor 2-deoxy-D-ribose or with agonistic-CD95-antibody pronounced this effect even more implicating a higher sensitivity to reactive oxygen species and a higher functional CD95 expression, respectively. In addition, expression of the activation markers HLA-DR and CD95 was significantly increased in CD3+-cells of aged subjects, while expression of CD25 did not seem to be affected by age. Expression of Bcl-2 was increased in aging and correlated with the number of apoptotic cells.
The relevance of physiological immune aging is of great interest with respect to determining disorders with pathologic immune function in aging individuals. In recent years, the relevance of changes in peripheral lymphocytes in age-associated neurologic diseases has become more evident. Due to the lack of immunological studies, covering more than one event after mitogenic activation, we envisaged a new concept in the present study, aiming to investigate several events, starting from T cell receptor (TCR) ligation up to T cell proliferation. In addition, we addressed the question whether changes are present in the subsets (CD4, CD8) with aging. Phosphorylation of tyrosine residues declines with increasing age in CD4+ cells. Fewer levels of CD69 positive cells after 4 h mitogenic activation, altered expression of cytokines (IL2, IFN-gamma and TNF-alpha; 22 h) and lower proliferation (72 h) were determined in aging. Moreover, it could be shown that CD8+ lymphocytes react more effectively to mitogenic stimulation with reference to CD69 expression and proliferation in both age groups (<35 and >60 years old). These data indicate that T cell activation, mediated by TCR engagement, is significantly impaired in aging and both subsets are affected. However, bypassing the TCR does not fully restore T cell function, indicating that there are more mechanisms involved than impaired signal transduction through TCR only. The results will be discussed in relation to their relevance in neurodegenerative and psychiatric disorders.
Enhanced apoptosis and elevated levels of reactive oxygen species (ROS) play a major role in aging. In addition, several neurodegenerative diseases are associated with increased oxidative stress and apoptosis in neuronal tissue. Antioxidative treatment has neuro-protective effects. The aim of the present study was to evaluate changes of susceptibility to apoptotic cell death by oxidative stress in aging and its inhibition by the antioxidant Ginkgo biloba extract EGb761. We investigated basal and ROS-induced levels of apoptotic lymphocytes derived from the spleen in young (3 months) and old (24 months) mice. ROS were induced by 2-deoxy-D-ribose (dRib) that depletes the intracellular pool of reduced glutathione. Lymphocytes from aged mice accumulate apoptotic cells to a significantly higher extent under basal conditions compared to cells from young mice. Treatment with dRib enhanced this difference, implicating a higher sensitivity to ROS in aging. Apoptosis can be reduced in vitro by treatment with EGb761. In addition, mice were treated daily with 100mg/kg EGb761 per os over a period of two weeks. ROS-induced apoptosis was significantly reduced in the EGb761 group. Interestingly, this effect seemed to be more pronounced in old mice.
The bile acid activated transcription factor farnesoid X receptor (FXR) regulates numerous metabolic processes and is a rising target for the treatment of hepatic and metabolic disorders. FXR agonists have revealed efficacy in treating non-alcoholic steatohepatitis (NASH), diabetes and dyslipidemia. Here we characterize imatinib as first-in-class allosteric FXR modulator and report the development of an optimized descendant that markedly promotes agonist induced FXR activation in a reporter gene assay and FXR target gene expression in HepG2 cells. Differential effects of imatinib on agonist-induced bile salt export protein and small heterodimer partner expression suggest that allosteric FXR modulation could open a new avenue to gene-selective FXR modulators.
The goal of this thesis was to gain further insight into the binding behavior of ligands in the heptahelical domain (HD) of group I metabotropic glutamate receptors (mGluRs). This was realized by the establishment of strategies for the detection and optimization of molecules acting as non-competitive antagonists of group I mGluRs (mGluR1/5). These strategies should guarantee high diversity in the retrieved chemotypes of the detected compounds not resembling original reference molecules (“scaffold-hopping”). The detection of new scaffolds, in turn, was divided into two approaches: First the development of pharmacological assays to screen compounds at a certain target for bioactivity (here: affinity towards the allosteric recognition site of mGluR1 and mGluR5), and second the evaluation of computer assisted methods for the identification of virtual hits to be screened afterwards on the pharmacological assays established before. Promising molecules should be optimized with respect to activity/affinity and selectivity, their binding mode investigated and, finally, compared to existing lead compounds. Initially, membrane based binding assays for the HD of mGlu1 and mGlu5 receptors with enhanced throughput (shifting from 24-well plates to 96-well plates) were set up. For the mGluR1 assay the potent antagonist EMQMCM exhibited high affinity towards the binding site (Ki ~3nM), which is in accordance with published data from Mabire et al. (functional IC50 3nM). For mGluR5 the reference antagonist MPEP binds with high affinity to the receptor (binding IC50 13.8nM), which confirmed earlier findings from Anderson et al. (binding IC50 15nM). In another series of experiments the properties of rat cerebellar (mGluR1) and corticalmembranes (mGluR5) as well as of radiotracers were investigated by means of binding saturation studies and kinetic experiments. Furthermore, the influence of the solvent DMSO, necessary for compound screening of lipophilic substances, on positive and negative controls was evaluated. As the precise architecture of the HD of mGluR1 is still not known our efforts in identifying new ligands for this receptor focused on the ligand-based approach. All computer assisted methods that were applied to virtually screen large compound collections and to retrieve potential hits (“activity-enriched subsets”) acting at the heptahelical domain of mGluR1 relied on the existence of a valid dataset of reference molecules. This was realized by an initial compilation of a mGluR reference data collection comprising in total 357 entries predominantly negative but also some positive allosteric modulators for mGluR1 and mGluR5. In the next step a pharmacophore model for non-competitive mGluR1 antagonists was constructed. It was based upon six selective, potent and structurally diverse ligands. Prospective virtual screening was performed using the CATS atom-pair descriptor. The Asinex Gold-Collection was screened for each seed compound and some of the most similar compounds (according to the CATS descriptor) were ordered and tested forbinding affinity and functional activity at mGluR1. A high hit rate of approximately 26% (IC50 < 15 micro M) was yielded confirming the applicability of this method. One compound exerted functional activity below one micro molar (IC50-value of C-07:362nM ± 0.03). Moreover, non-linear principal component analysis was employed. Again the Asinex vendor database served as test database and was filtered by the pharmacophore model for mGluR1 established before. Test molecules that were adjacently located with mGluR1 antagonist references were selected. 15 compounds were tested on mGluR1 in binding and functional assays and three of them exhibited functional activity (IC50) below 15 micro M. The most potent molecule P-06 revealed an IC50-value of 1.11 micro M (± 0.41). The COBRA database comprising 5,376 structurally diverse bioactive molecules affecting various targets was encoded with the CATS descriptor and used for training two selforganizing maps (SOM). The encoded mGluR reference data collection was projected onto this map according to the SOM algorithm. This projection allowed to clearly distinguish between antagonists of mGluR1 and mGluR5 subtype. 28 compounds were ordered and tested on activity and affinity for mGluR1. They exhibited functional activity down to the sub-micro molar range (IC50-value of S-08: 744nM ± 0.29) yielding a final hit rate of 46% (<15 micro M). Then, the Asinex collection was screened using the SOM approach. For a predicted target panel including the muscarinic mACh (M1) receptor, the histamine H1-receptor and the dopamine D2/D3 receptors, the tested mGluR ligands exhibited the calculated binding pattern. This virtual screening concept might provide a basis for early recognition of potential sideeffects in lead discovery. We superimposed a set of 39 quinoline derivatives as non-competitive mGluR1 antagonists that were recently published by Mabire and co-workers. A CoMFA model (QSAR) was established and the influence of several side chains on functional activity was investigated. The coumarine derivative C-07 was obtained as a result of similarity searching. Starting from this compound a series of chemical derivatives was synthesized. This led to the discovery of potent (B-28, IC50: 58nM ± 0.008; Ki: 293nM ± 0.022) and selective (rmGluR5 IC50: 28.6 micro M) mGluR1 antagonists. From a homology model of mGluR1 we derived a potential binding mode for coumarines within the allosteric transmembrane region. Potential interacting patterns with amino acids were proposed considering the difference of the binding pockets between rat and human receptors. The proposed binding modes for quinolines (here:EMQMCM) and coumarines (here:B-04) were compared and discussed considering in particular the influence on activity of several side chains of quinolines obtained from the QSAR studies. The present studies demonstrated the applicability of ligand-based virtual screening for non-competitive antagonists of a G-protein coupled receptor, resulting in novel, potent and selective agents.
While interleukin (IL)-1β is a potent pro-inflammatory cytokine involved in host defense, high levels can cause life-threatening sterile inflammation including systemic inflammatory response syndrome. Hence, the control of IL-1β secretion is of outstanding biomedical importance. In response to a first inflammatory stimulus such as lipopolysaccharide, pro-IL-1β is synthesized as a cytoplasmic inactive pro-form. Extracellular ATP originating from injured cells is a prototypical second signal for inflammasome-dependent maturation and release of IL-1β. The human anti-protease alpha-1 antitrypsin (AAT) and IL-1β regulate each other via mechanisms that are only partially understood. Here, we demonstrate that physiological concentrations of AAT efficiently inhibit ATP-induced release of IL-1β from primary human blood mononuclear cells, monocytic U937 cells, and rat lung tissue, whereas ATP-independent IL-1β release is not impaired. Both, native and oxidized AAT are active, suggesting that the inhibition of IL-1β release is independent of the anti-elastase activity of AAT. Signaling of AAT in monocytic cells involves the lipid scavenger receptor CD36, calcium-independent phospholipase A2β, and the release of a small soluble mediator. This mediator leads to the activation of nicotinic acetylcholine receptors, which efficiently inhibit ATP-induced P2X7 receptor activation and inflammasome assembly. We suggest that AAT controls ATP-induced IL-1β release from human mononuclear blood cells by a novel triple-membrane-passing signaling pathway. This pathway may have clinical implications for the prevention of sterile pulmonary and systemic inflammation.
Many cases of early-onset inherited Alzheimer's disease (AD) are caused by mutations in the presenilin-1 (PS1) gene. Expression of PS1 mutations in cell culture systems and in primary neurons from transgenic mice increases their vulnerability to cell death. Interestingly, enhanced vulnerability to cell death has also been demonstrated for peripheral lymphocytes from AD patients. We now report that lymphocytes from PS1 mutant transgenic mice show a similar hypersensitivity to cell death as do peripheral cells from AD patients and several cell culture systems expressing PS1 mutations. The cell death-enhancing action of mutant PS1 was associated with increased production of reactive oxygen species and altered calcium regulation, but not with changes of mitochondrial cytochrome c. Our study further emphasizes the pathogenic role of mutant PS1 and may provide the fundamental basis for new efforts to close the gap between studies using neuronal cell lines transfected with mutant PS1, neurons from transgenic animals, and peripheral cells from AD patients. Copyright 2001 Academic Press.